Inhibition of angiogenesis by interleukin 4

Olga V. Volpert, Tim Fong, Alisa E. Koch, Jeffrey D. Peterson, Carl Waltenbaugh, Robert I. Tepper, Noël P. Bouck*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

197 Scopus citations


Interleukin (IL)-4, a crucial modulator of the immune system and an active antitumor agent, is also a potent inhibitor of angiogenesis. When incorporated at concentrations of 10 ng/ml or more into pellets implanted into the rat cornea or when delivered systemically to the mouse by intraperitoneal injection, IL-4 blocked the induction of corneal neovascularization by basic fibroblast growth factor. IL-4 as well as IL-13 inhibited the migration of cultured bovine or human microvascular cells, showing unusual dose-response curves that were sharply stimulatory at a concentration of 0.01 ng/ml but inhibitory over a wide range of higher concentrations. Recombinant cytokine from mouse and from human worked equally well in vitro on bovine and human endothelial cells and in vivo in the rat, showing no species specificity. IL-4 was secreted at inhibitory levels by activated murine T helper (T(H)0) cells and by a line of carcinoma cells whose tumorigenicity is known to be inhibited by IL-4. Its ability to cause media conditioned by these cells to be antiangiogenic suggested that the antiangiogenic activity of IL-4 may play a role in normal physiology and contribute significantly to its demonstrated antitumor activity.

Original languageEnglish (US)
Pages (from-to)1039-1046
Number of pages8
JournalJournal of Experimental Medicine
Issue number6
StatePublished - Sep 21 1998


  • Cornea assay
  • Endothelial cell
  • Migration
  • Neovascularization
  • Tumor angiogenesis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Inhibition of angiogenesis by interleukin 4'. Together they form a unique fingerprint.

Cite this